Literature DB >> 32860100

Prevalence of and factors associated to chronic kidney disease and hypertension in a cohort of children with juvenile idiopathic arthritis.

Maria Francesca Gicchino1, Anna Di Sessa1, Stefano Guarino1, Emanuele Miraglia Del Giudice1, Alma Nunzia Olivieri1, Pierluigi Marzuillo2.   

Abstract

We evaluated chronic kidney disease (CKD) (proteinuria or estimated glomerular filtration rate < 60 mL/min/1.73 m2) or hypertension prevalence in 110 children with juvenile idiopathic arthritis (JIA). CKD and hypertension were clustered under the umbrella term of "renal injury". Median age at the last visit was 14 years. Nine out of 110 (8.1%) patients showed renal injury (8 hypertension, 1 proteinuria). Patients with renal injury presented higher age at last visit, longer duration of active JIA, shorter intervals free from JIA relapses, longer duration of non-steroidal anti-inflammatory drugs (NSAIDs) treatment but with similar cumulative NSAIDs dose and higher rate of methotrexate (MTX) prescription, longer time of MTX administration, and higher cumulative MTX dose compared to patients without renal injury. At the last visit, patients with and without renal injury presented similar prevalence of active disease. The cumulative proportion of patients free from renal injury at 240 months since JIA onset was 40.72% for all population; while the cumulative proportion was 23.7% for patients undergoing NSAIDs+MTX treatment and 100% for those undergoing NSAIDs (p = 0.039) treatment.
Conclusion: About 8% of the children with JIA develop hypertension or CKD. The main risk factor was longer exposure to both NSAIDs and MTX due to a more severe form of the disease. What is Known •Anecdotal reports showed that rarely juvenile idiopathic arthritis (JIA) could present renal involvement due to prolonged and uncontrolled inflammation (renal amyloidosis) or to long exposure to anti-rheumatic drugs. •No cohort studies investigated renal health in children with JIA. What is new •About 8% of the children with JIA developed hypertension or chronic kidney disease. •The main risk factor was long exposure to non-steroidal anti-inflammatory drugs and methotrexate for patients suffering from a more severe form of the disease. •In JIA patients, periodic evaluation of renal function, blood pressure and proteinuria should be warranted.

Entities:  

Keywords:  Children; Hypertension; Juvenile idiopathic arthritis; Methotrexate; NSAIDs; Proteinuria; Renal injury

Mesh:

Substances:

Year:  2020        PMID: 32860100     DOI: 10.1007/s00431-020-03792-4

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  4 in total

1.  Methotrexate in juvenile idiopathic arthritis: answers and questions.

Authors:  A Ravelli; A Martini
Journal:  J Rheumatol       Date:  2000-08       Impact factor: 4.666

2.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

3.  Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.

Authors:  Carol A Wallace; Nicolino Ruperto; Edward Giannini
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

4.  Juvenile rheumatoid arthritis with renal amyloidosis: a 23-year survival.

Authors:  A J Cusano; J H Bland; D J Lapenas; A S Cohen; C Libbey
Journal:  J Rheumatol       Date:  1982 Nov-Dec       Impact factor: 4.666

  4 in total
  4 in total

1.  Uric acid could be a marker of cardiometabolic risk and disease severity in children with juvenile idiopathic arthritis.

Authors:  Maria Francesca Gicchino; Pierluigi Marzuillo; Sarah Zarrilli; Rosa Melone; Stefano Guarino; Emanuele Miraglia Del Giudice; Alma Nunzia Olivieri; Anna Di Sessa
Journal:  Eur J Pediatr       Date:  2022-10-14       Impact factor: 3.860

Review 2.  Traditional Chinese Medicine in Treating Primary Podocytosis: From Fundamental Science to Clinical Research.

Authors:  Lirong Lin; En Tian; Jiangwen Ren; Zhifeng Wu; Junhui Deng; Jurong Yang
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

3.  Preliminary observations on the immunogenicity and safety of vaccines to prevent COVID-19 in patients with juvenile idiopathic arthritis.

Authors:  Maria Francesca Gicchino; Fabio Giovanni Abbate; Alessia Amodio; Emanuele Miraglia Del Giudice; Alma Nunzia Olivieri
Journal:  Acta Paediatr       Date:  2022-07-08       Impact factor: 4.056

Review 4.  Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature.

Authors:  Sylwester Drożdżal; Kacper Lechowicz; Bartosz Szostak; Jakub Rosik; Katarzyna Kotfis; Anna Machoy-Mokrzyńska; Monika Białecka; Kazimierz Ciechanowski; Barbara Gawrońska-Szklarz
Journal:  Pharmacol Res Perspect       Date:  2021-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.